Close rivalries among European multiple sclerosis medical affairs teams. Will your team come out on top?
In Europe, one multiple sclerosis medical affairs team leads the way in terms of interaction frequency and overall quality of interactions, but there’s room for improvement in other areas. The 150 neurologists from the EU5 markets (France, Germany, Italy, Spain and the UK) we polled provide insights on several medical affairs teams, and opinions are mixed. Improvement in at least one specific area is needed, but are those targeted improvements enough to put your team ahead of the competition?
Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: Multiple Sclerosis (EU5). Comparing 11 major multiple sclerosis treatments from Sanofi, Bayer, Biogen, Teva, Novartis, and Merck Group, this report reveals:
That’s actionable information you can use to turn your team into one that doctors rely on.
Interested in the US market? Click here to see the US Edition.
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 11 medical affairs teams—answering important questions like:
What do doctors need?
Does your medical affairs team deliver?
What needs improvement?
We surveyed 150 neurologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
We conducted the survey between May 3-11, 2018.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved